Yahoo Finance

Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

Jasper is a clinical-stage biotechnology company focused on developing briquilimab as a therapeutic for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal antibody that ...
Nasdaq

Jasper: First patient dosed in ETESIAN clinical study of briquilimab in asthma

Jasper Therapeutics (JSPR), announced that the first patient has been dosed in Jasper’s Phase 1b/2a clinical challenge study evaluating briquilimab in allergic asthma, called ETESIAN,Evaluating The ...
manilatimes

Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation

The presentation slides and a link to the live and archived webcast will also be available on the Events & News - Events page of Jasper's Investor Relations website. Jasper is a clinical-stage ...
Nasdaq

Jasper Therapeutics Reports Promising BEACON Study Results for Briquilimab in Chronic Spontaneous Urticaria Amid Drug Product Lot Investigation

Jasper Therapeutics, Inc. announced promising results from its BEACON Phase 1b/2a study of briquilimab, an antibody therapy targeting mast cell diseases like chronic spontaneous urticaria (CSU). In ...